A Trasylol lawyer can help Trasylol Injury

Two recently published research studies have linked Trasylol® (Generic: Aprotinin), a drug often used to prevent blood loss during CABG surgery, to an increased risk of kidney problems, heart attacks, and strokes.

Patients who experience complications after CABG surgery should contact their medical providers to determine if Trasylol® was used for their procedure. If Trasylo® was administered, the drug may have factored into post-surgical complications.

The United States Food and Drug Administration (FDA) issued a public health advisory on February 8, 2006. The advisory states that the FDA is conducting a safety evaluation for Trasylol® to assess the drug’s risks. Doctors are warned to carefully weigh the potential benefits and risks of Trasylol® before administering the drug to patients. Patients who take Trasylol® should be monitored for toxicity to the kidneys, heart, and central nervous system. Adverse events must be promptly reported to Bayer or the FDA Medwatch program.

If you know someone who experienced kidney problems, heart attack, or stroke following CABG surgery, contact Jim S. Adler & Associates today to schedule a free case evaluation.

Manufactured by Bayer, Trasylol® is now a highly controversial drug and the subject of a number of lawsuits. Those taking Trasylol may experience heightened risk of conditions including heart attack, stroke, kidney failure and many others.

Contact a Trasylol lawyer today

If you’ve been harmed by the drug Trasylol®, you may have a case against the manufacturer. Jim S. Adler helps people injured by Trasylol and other defective drugs.

Jim S. Adler & Associates is a Texas-based law firm whose commitment to representing injured people began in 1973 in Houston, Texas. Based on experience, leadership and trust, our firm is dedicated to improving the quality of life for our clients.

 

 

TRASYLOL ARTICLES...



Bayer addresses Trasylol issue

Bayer Pharmaceuticals Corp., in collaboration with the U.S. FDA, agrees to inform all healthcare professionals of important safety revisions to the U.S. product information for Trasylol (aprotinin injection) following an FDA Advisory Committee meeting.

These safety revisions relate primarily to renal function and hypersensitivity.


Read more...
 

Copyright © 2006-2008 Jim S. Adler & Associates, All Rights Reserved.
The content on JimAdler.com should NOT be taken as a substitute for advice by a competent attorney or medical professional. The site is sponsored by Jim S. Adler & Associates (Principal Office: Houston, Texas Phone: 800-505-1414). Use of this website or submission of an online form does NOT constitute the forming of an attorney-client relationship. Accordingly, no attorney/client relationship is formed until you are contacted by an attorney from Jim S. Adler & Associates and you sign a client agreement. Information contained on JimAdler.com, including, but not limited to written text, images, informational articles, and on or off site links, has not been prepared, endorsed, or reviewed by any form of licensed medical professional, including but not limited to physicians, doctors, and so on. Nothing on this website should be taken as medical advice, but instead should act as a useful resource in providing general information that may be useful to members of the general public. All visitors are encouraged to consult with a physician or other licensed medical professional for any form of medical advice.